The annual general meeting of the shareholders of Nymox
Pharmaceutical Corporation (NASDAQ: NYMX) was highlighted by an update
and review of current product development by the Company's President
and CEO, Dr. Paul Averback. Newly elected to the Board of Directors
were Professor David Morse, Ph.D., Roger Guy, M.D., Paul F. McDonald,
and Randall Lanham.
Dr. Paul Averback reviewed important developments for the Company's products, including NX-1207, the Company's investigational new drug for benign prostatic hyperplasia (BPH). Dr. Averback outlined the progress of the Company's research and development programs for new Alzheimer's disease therapeutics, proprietary treatments for E. coli O157 food contamination, and other novel treatments. Dr. Averback emphasized the Company's strategy of building a large worldwide patent portfolio in support of its proprietary product development programs. Currently Nymox and its subsidiaries own or have licensed exclusive rights to several hundred patents and patent applications in the U.S. and other countries around the world.
Randall Lanham is an Orange County attorney with extensive experience in securities law and corporate finances. Mr. Lanham has vast experience in both domestic and international corporate legal matters. Paul F. McDonald, a graduate in law of McGill University, has been Vice-President of the Montreal Exchange, principal owner and president of a stock-exchange firm, and a longtime director of the Quebec Industrial Development Corporation, and brings a lifetime of experience as a member of the investment industry to the Nymox board. Professor David Morse, Ph.D. is a Professor at the University of Montreal and a world expert in the biochemistry, proteomics and genomics of cell function. Professor Morse has published extensively in the peer-reviewed scientific literature, including papers in journals such as Science, Nature, Cell, Proceedings of the National Academy of Science, and the Journal of Biological Chemistry. Roger Guy, M.D., is a highly experienced medical doctor who has served as a national examiner. Dr. Guy has broad human clinical trial and business managerial experience.
More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
Dr. Paul Averback reviewed important developments for the Company's products, including NX-1207, the Company's investigational new drug for benign prostatic hyperplasia (BPH). Dr. Averback outlined the progress of the Company's research and development programs for new Alzheimer's disease therapeutics, proprietary treatments for E. coli O157 food contamination, and other novel treatments. Dr. Averback emphasized the Company's strategy of building a large worldwide patent portfolio in support of its proprietary product development programs. Currently Nymox and its subsidiaries own or have licensed exclusive rights to several hundred patents and patent applications in the U.S. and other countries around the world.
Randall Lanham is an Orange County attorney with extensive experience in securities law and corporate finances. Mr. Lanham has vast experience in both domestic and international corporate legal matters. Paul F. McDonald, a graduate in law of McGill University, has been Vice-President of the Montreal Exchange, principal owner and president of a stock-exchange firm, and a longtime director of the Quebec Industrial Development Corporation, and brings a lifetime of experience as a member of the investment industry to the Nymox board. Professor David Morse, Ph.D. is a Professor at the University of Montreal and a world expert in the biochemistry, proteomics and genomics of cell function. Professor Morse has published extensively in the peer-reviewed scientific literature, including papers in journals such as Science, Nature, Cell, Proceedings of the National Academy of Science, and the Journal of Biological Chemistry. Roger Guy, M.D., is a highly experienced medical doctor who has served as a national examiner. Dr. Guy has broad human clinical trial and business managerial experience.
More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.